Literature DB >> 20425143

Long-term use of pramipexole in bipolar depression: a naturalistic retrospective chart review.

Rif S El-Mallakh1, Praveen Penagaluri, Arun Kantamneni, Yonglin Gao, Rona J Roberts.   

Abstract

A naturalistic retrospective chart review of all patients given pramipexole for bipolar depression in addition to their mood stabilizers was undertaken. Sixteen patients were followed for an average of 6.7 +/- SD 9.0 months. Half of the patients stopped the pramipexole an average of 2 months after starting it. For all patients, depressed mood, and the total profile of depressive symptoms improved significantly within 4 weeks and remained significantly improved for as long as 36 weeks. Both global function (GAF), and global impression (CGI) improved with pramipexole. Irritability and insomnia both increased slightly initially, and then subsided. There were no changes in mania ratings for up to 36 months. Long-term outcome of adjunctive pramipexole appears to be adequate, with apparent maintenance of effect for over 9 months.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20425143     DOI： 10.1007/s11126-010-9130-6

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN： 0033-2720


  10 in total

1.  The effect of repeated treatment with pramipexole on the central dopamine D3 system.

Authors:  J Maj; Z Rogói; W Margas; M Kata; M Dziedzicka-Wasylewska
Journal:  J Neural Transm (Vienna)       Date:  2000       Impact factor: 3.575

2.  A clinical monitoring form for mood disorders.

Authors:  Gary S Sachs; Constance Guille; Stephanie L McMurrich
Journal:  Bipolar Disord       Date:  2002-10       Impact factor: 6.744

3.  Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP.

Authors:  M K Spearing; R M Post; G S Leverich; D Brandt; W Nolen
Journal:  Psychiatry Res       Date:  1997-12-05       Impact factor: 3.222

4.  A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease.

Authors: 
Journal:  Eur J Neurol       Date:  1998-05       Impact factor: 6.089

5.  Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression.

Authors:  C B Nemeroff; D L Evans; L Gyulai; G S Sachs; C L Bowden; I P Gergel; R Oakes; C D Pitts
Journal:  Am J Psychiatry       Date:  2001-06       Impact factor: 18.112

6.  Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.

Authors:  Andrew A Nierenberg; Michael J Ostacher; Joseph R Calabrese; Terence A Ketter; Lauren B Marangell; David J Miklowitz; Sachiko Miyahara; Mark S Bauer; Michael E Thase; Stephen R Wisniewski; Gary S Sachs
Journal:  Am J Psychiatry       Date:  2006-02       Impact factor: 18.112

7.  Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126).

Authors:  Eduard Vieta; Trisha Suppes; Ivan Eggens; Inger Persson; Björn Paulsson; Martin Brecher
Journal:  J Affect Disord       Date:  2008-06-24       Impact factor: 4.839

Review 8.  A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network.

Authors:  Robert M Post; Gabriele S Leverich; Willem A Nolen; Ralph W Kupka; Lori L Altshuler; Mark A Frye; Trisha Suppes; Susan McElroy; Paul Keck; Heinze Grunze; Jorg Walden
Journal:  Bipolar Disord       Date:  2003-12       Impact factor: 6.744

9.  Effectiveness of adjunctive antidepressant treatment for bipolar depression.

Authors:  Gary S Sachs; Andrew A Nierenberg; Joseph R Calabrese; Lauren B Marangell; Stephen R Wisniewski; Laszlo Gyulai; Edward S Friedman; Charles L Bowden; Mark D Fossey; Michael J Ostacher; Terence A Ketter; Jayendra Patel; Peter Hauser; Daniel Rapport; James M Martinez; Michael H Allen; David J Miklowitz; Michael W Otto; Ellen B Dennehy; Michael E Thase
Journal:  N Engl J Med       Date:  2007-03-28       Impact factor: 91.245

10.  Pramipexole for bipolar II depression: a placebo-controlled proof of concept study.

Authors:  Carlos A Zarate; Jennifer L Payne; Jaskaran Singh; Jorge A Quiroz; David A Luckenbaugh; Kirk D Denicoff; Dennis S Charney; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2004-07-01       Impact factor: 13.382
  10 in total
  4 in total

Review 1.  New drugs for bipolar disorder.

Authors:  Marsal Sanches; Jair C Soares
Journal:  Curr Psychiatry Rep       Date:  2011-12       Impact factor: 5.285

2.  Study protocol for a randomised placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression (the PAX-BD study).

Authors:  Lumbini Azim; Paul Hindmarch; Georgiana Browne; Thomas Chadwick; Emily Clare; Paul Courtney; Lyndsey Dixon; Nichola Duffelen; Tony Fouweather; John R Geddes; Nicola Goudie; Sandy Harvey; Timea Helter; Eva-Maria Holstein; Garry Martin; Phil Mawson; Jenny McCaffery; Richard Morriss; Judit Simon; Daniel Smith; Paul R A Stokes; Jenn Walker; Chris Weetman; Faye Wolstenhulme; Allan H Young; Stuart Watson; R Hamish McAllister-Williams
Journal:  BMC Psychiatry       Date:  2021-07-05       Impact factor: 3.630

3.  Current and emerging therapies for the management of bipolar disorders.

Authors:  Rif S El-Mallakh; Ahmed Z Elmaadawi; Yonglin Gao; Kavita Lohano; R Jeannie Roberts
Journal:  J Cent Nerv Syst Dis       Date:  2011-08-07

Review 4.  The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment.

Authors:  A H Ashok; T R Marques; S Jauhar; M M Nour; G M Goodwin; A H Young; O D Howes
Journal:  Mol Psychiatry       Date:  2017-03-14       Impact factor: 15.992
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.